A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

07 Feb 2025 According to a Quince Therapeutics media release, the company announced enrollement of 46 participants to date in this trial, Phase 3 NEAT clinical trial nearing 50% enrollment;
28 Jan 2025 According to a Quince Therapeutics media release, company announced that it will host an investor webinar to discuss enrollment update on the company's ongoing Phase 3 NEAT clinical trial. The virtual webinar event will take place on Friday, February 7, 2025, beginning at 10:00 a.m. Eastern Time.
13 Nov 2024 According to a Quince Therapeutics media release, company is expecting to complete enrollment in the second quarter of 2025 .

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com